Short answer
Solventum (SOLV) filed its fiscal 2024 10-K annual report with the SEC on Feb 28, 2025. It reported revenue of $8.3B (+0.7% year over year) and net income of $479M.
- Top risk flagged: Regulatory/legal risk: Ongoing impact of 3M Spin-Off-related costs, including profit mark-ups on transition service agreements and separation expenses
FY2024 key financial metrics · XBRL
- Revenue
- $8.3B
- +0.7% YoY
- Net income
- $479M
- −64.4% YoY
- Operating margin
- 12.6%
- −8.1 pp YoY
- Gross margin
- 55.6%
- −1.6 pp YoY
- EPS (diluted)
- $2.76
- −64.6% YoY
- ROE
- 16.2%
- +4.7 pp YoY
- Operating cash flow
- $1.2B
- −38.1% YoY
Source: XBRL data from the Solventum (SOLV) FY2024 10-K on SEC EDGAR. USD.
Solventum FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model pivot implied by separation from 3M Company via Separation and Distribution Agreement dated March 31, 2024
- Introduction of multiple transition agreements with 3M supporting independent operations post-separation
- New executive addition: Doug Jones as MedSurg VP Sales US & Canada with compensation ~$525,000
- Governance updates: Adoption of Recoupment Policy April 1, 2024 and amendments to bylaws in Sept 2024
- Most notable fact: 2024 marked spin-off from 3M with extensive transition contracts and standalone governance infrastructure established
Management Discussion & Analysis
- Revenue for fiscal year 2025 not explicitly stated, no YoY dollar change disclosed
- Management notes risks from loss of 3M brand and debt burden affecting profitability and future capital allocation
Risk Factors
- Regulatory/legal risk: Ongoing impact of 3M Spin-Off-related costs, including profit mark-ups on transition service agreements and separation expenses
- Geopolitical/macroeconomic risk: Foreign currency transaction effects and hedging reduced pre-tax income by approx. $23 million in 2024
- Operational/supply chain risk: Increased cost of inventory and transition manufacturing agreements with 3M driving product cost increase by 2.0% in 2024
- Competitive/market disruption risk: MedSurg volume decline in traditional negative pressure wound therapy due to product portfolio shifts and market demand changes
- Financial/structural risk: $6.9 billion senior notes and $1.5 billion senior term loans issued in early 2024, with $300 million principal prepaid, changing capital structure post-Spin-Off
Generated from the filing text; verify against the original. How to read a 10-K
Other Solventum annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.